Direkt zum Inhalt
Merck

ABCs of Neonatal Cardiac Anesthesia.

Artificial organs (2013-01-12)
Chris Chin
ZUSAMMENFASSUNG

Congenital heart disease (CHD) is relatively common and there are treatment options for virtually every form of CHD. With good care, the majority of babies can survive to adulthood; however, CHD remains a significant cause of death in infancy and neonates are especially vulnerable. In order to manage these patients, a clear understanding of the underlying pathophysiology and the planned surgical procedure is important. However, attention to detail and meticulous care are equally important, and, in addition, there are several management strategies that may standardize practice and can improve outcome.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Magnesiumsulfat, anhydrous, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Magnesiumsulfat Heptahydrat, ACS reagent, ≥98%
Sigma-Aldrich
Magnesiumsulfat Heptahydrat, ReagentPlus®, ≥99.0%
Sigma-Aldrich
Magnesiumsulfat, BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Magnesiumsulfat Heptahydrat, BioReagent, for molecular biology, suitable for plant cell culture, ≥99.0%
Sigma-Aldrich
Magnesiumsulfat, puriss. p.a., drying agent, anhydrous, ≥98.0% (KT), powder (very fine)
Sigma-Aldrich
Magnesiumsulfat -Lösung, for molecular biology, 1.00 M±0.04 M
Sigma-Aldrich
Magnesiumsulfat Heptahydrat, BioUltra, ≥99.5% (KT)
Sigma-Aldrich
Magnesiumsulfat -Lösung, BioUltra, for molecular biology
Sigma-Aldrich
Magnesiumsulfat, ≥99.99% trace metals basis
Sigma-Aldrich
Magnesiumsulfat Heptahydrat, BioXtra, ≥99.0%